Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Missense variants in CMS22 patients reveal that PREPL has both enzymatic and nonenzymatic functions
Yenthe Monnens, … , Matteo Dal Peraro, John W.M. Creemers
Yenthe Monnens, … , Matteo Dal Peraro, John W.M. Creemers
Published July 30, 2024
Citation Information: JCI Insight. 2024;9(17):e179276. https://doi.org/10.1172/jci.insight.179276.
View: Text | PDF
Research Article Endocrinology Genetics

Missense variants in CMS22 patients reveal that PREPL has both enzymatic and nonenzymatic functions

  • Text
  • PDF
Abstract

Congenital myasthenic syndrome-22 (CMS22, OMIM 616224) is a rare genetic disorder caused by deleterious genetic variation in the prolyl endopeptidase-like (PREPL) gene. Previous reports have described patients with deletions and nonsense variants in PREPL, but nothing is known about the effect of missense variants in the pathology of CMS22. In this study, we have functionally characterized missense variants in PREPL from 3 patients with CMS22, all with hallmark phenotypes. Biochemical evaluation revealed that these missense variants do not impair hydrolase activity, thereby challenging the conventional diagnostic criteria and disease mechanism. Structural analysis showed that the variants affect regions most likely involved in intraprotein or protein-protein interactions. Indeed, binding to a selected group of known interactors was differentially reduced for the 3 variants. The importance of nonhydrolytic functions of PREPL was investigated in catalytically inactive PREPL p.Ser559Ala cell lines, which showed that hydrolytic activity of PREPL is needed for normal mitochondrial function but not for regulating AP1-mediated transport in the transgolgi network. In conclusion, these studies showed that CMS22 can be caused not only by deletion and truncation of PREPL but also by missense variants that do not necessarily result in a loss of hydrolytic activity of PREPL.

Authors

Yenthe Monnens, Anastasia Theodoropoulou, Karen Rosier, Kritika Bhalla, Alexia Mahy, Roeland Vanhoutte, Sandra Meulemans, Edoardo Cavani, Aleksandar Antanasijevic, Irma Lemmens, Jennifer A. Lee, Catherine J. Spellicy, Richard J. Schroer, Ricardo A. Maselli, Chamindra G. Laverty, Patrizia Agostinis, David J. Pagliarini, Steven Verhelst, Maria J. Marcaida, Anne Rochtus, Matteo Dal Peraro, John W.M. Creemers

×

Figure 1

CMS22 patient PREPL variants remain catalytically active.

Options: View larger image (or click on image) Download as PowerPoint
CMS22 patient PREPL variants remain catalytically active.
(A) The 3 CMS2...
(A) The 3 CMS22 mutants and the catalytically inactive PREPL p.Ser559Ala mapped on the PREPL structure. (B) Catalytic activity using FP-Biotin activity-based probe binding. Blot: Streptavidin = FP-biotin signal, Flag = PREPL signal. Graph: quantitative reactivity of WT and variant PREPL to the FP-biotin probe normalized to total PREPL abundance (n = 4) (C) Isothermal titration calorimetry measurements of the binding of inhibitor 8 to WT, p.Ser559Ala, p.Arg243Cys, and p.Arg647Gln PREPL. Shown are single representative traces and each stated KD value is the mean from n = 3 technical replicates. (D) Representative graph of DIFMUO cleavage by WT and variant PREPL and calculated relative activity (n = 3). RFU, relative fluorescence units. Statistical analysis was performed using 1-way ANOVA. Significance levels are shown as *P ≤ 0.05 **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts